suggested that pretreatment with EGFR-TKI can induce CD8+ T-cell responses in EGFR-mutant NSCLC tumors, which was further pronounced by sequential dual blockade of PD-1 and vascular endothelial growth factor receptor 2 (31). This evidence concerns the gene CD8A and non-small cell lung carcinoma.